Aksan G., Inci S., Nar G. et al. Serum neutrophil gelatinase-associated lipocalin levels in patients with non-dipper hypertension // Clin. Invest. Med. 2015. (2). 53-62.
Arutyunov G.P. Pathophysiological processes in kidneys of patients with a chronic heart failure // Serdechnaya nedostatochnost' = Russian Heart Failure Journal. 2008. (9). 243-250. [In Russian].
Belokhvostikova T.S., Orlova G.M., Fatakhonva O.A. et al. Neutrophil gelatinase-associated lipocalin in patients with a chronic kidney disease: clinical laboratory interrelations // Nefrologiya i dializ = Nephrology and Dialysis. 2011. 13. (3). 268-369. [In Russian].
Bielecka-Dabrowa A., Gluba-Brzozka A., Michalska-Kasiczak M. et al. The multi-biomarker approach for heart failure in patients with hypertension // Int. J. Mol. Sci. 2015. (5). 10715-33.
Blázquez-Medela A., García-Sánchez O., Blanco-Gozalo V. et al. Hypertension and hyperglycemia synergize to cause incipient renal tubular alterations resulting in increased NGAL urinary excretion in rats // PLoS One. 2014. 9. (8). e105988.
Blumczynski A., Sołtysiak J., Lipkowska K. et al. Hypertensive nephropathy in children — do we diagnose early enough? // Blood Press. 2012. (4). 233-234.
Bobbert T., Raila J., Schwarz F. et al. Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness // Atherosclerosis. 2010. 213. (2). 549–551.
Chazova I.E., Ratova L.G., Boytsov S.A. et al. Diagnostics and treatment of arterial hypertension // Sistemnye gipertenzii = Systemic hypertensions. 2010. (3). 5–26. [In Russian].
Choi K.M., Lee J.S., Kim E.J. et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease // Eur. J. Endocrinol. 2008. (2). 7-203.
Damman K., Masson S., Hillege H.L. et al. Tubular damage and worsening renal function in chronic heart failure // JACC Heart Fail. 2013. (5). 417–24.
Damman K., van Veldhuisen D.J., Navis G. et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure // Eur. J. Heart Fail. 2008. 10. (10). 997–1000.
Deinum J., Ronn B., Mathiesen E. et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus // Diabetologia. 1999. 42. 1006-1010.
Fliser D., Kronenberg F., Kielstein J.T. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study // J. Am. Soc. Nephrol. 2005. 16. 2456-2461.
Gaedeke J., Peters H., Noble N. et al. Angiotensin II, TGF-beta and renal fibrosis // Contrib. Nephrol. 2001. 135. 153–160.
Global status report on noncommunicable diseases 2010. Geneva: World Health Organization, 2011.
Kadioglu T., Uzunlulu M., Yigit Kaya S. et al. Urinary kidney injury molecule-1 levels as a marker of early kidney injury in hypertensive patients // Minerva Urol. Nefrol. 2016. 68. (5). 56–61.
Kaplanyan M.V. Prognostic criteria of a diabetic nephropathy in patients with diabetes mellitum type 1: abstract of thesis…doctor of medical sciences. Saint-Petersburg, 2016.
Khasun M, Kayukov I.G., GalkinaO.V. et al. Uromodulin and ion excretion in patients with glomerulopathy // Nefrologiya =Nephrology. 2016. (1). 51-56. [In Russian].
Kielstein J.T., Salpeter S.R., Bode-Boeger S.M. et al. Symmetric dimethylarginine as endogenous marker of renal function – a meta-analysis // Nephrol. Dial. Transplant. 2006. 21. (9). 2446-2451.
Ko G.J., Grigoryev D.N., Linfert D. et al. Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition // Am. J. Physiol. Renal Physiol. 2010. 298. (6). 72–83.
Kobalava Zh.D., Dmitrova T.B. Cardiorenal syndrome // Russkiy meditsinskiy zhurnal = Russian medical journal. 2003. (12). 699-701. [In Russian].
Kraydashenko O.V., Dolinnaya M.A. Role of biomarkers in assessment of nature of injury of kidneys at patientsidiopathic hypertensia // Klinicheskaya nefrologiya = Clinical nephrology. 2014. (3). 23-25. [In Russian].
Kuz'min O.B., Buchneva N.V., Pugacheva M.D. Renal hemodynamic mechanisms of formation of a hypertonic nephropathy // Nefrologiya = Nephrology. 2009. (4). 28–36. [In Russian].
Lopez-Giacoman S., Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage // World J. Nephrol. 2015. 4. (1).57-73.
Malgorzewicz S., Skrzypczak-Jankun E., Jankun J. Plasminogen activator inhibitor-1 in kidney pathology // Int. J. Mol. Med. 2013. (3). 503–510.
Mukhin N.A. Nephrology: national manual. Moscow, 2009. 445-477. [In Russian].
Nanchikeeva M.L. Early stage of kidney damage in patients with idiopathic hypertension: clinical value, principles of prevention: abstract of thesis…doctor of medical sciences. Moscow, 2010. [In Russian].
Peralta C.A., Katz R., Bonventre J.V. et al. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the MultiEthnic Study of Atherosclerosis (MESA) // Am. J. Kidney Dis. 2012. (6). 904–11.
Piepoli M.F., Hoes A.W., Agewall S. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) // Eur. Heart J. 2016. 37. (29)/ 2315-2381.
Porush J.G., Faubert P.F. Clinician's manual on hypertension, diabetes mellitus and nephropathy. L.: Science Press, 2001. 9-12.
Shalnova S., Kukushkin S., Manoshkina E. et al. Arterial hypertension and commitment of therapy // Vrach = Physician. 2009. (12). 39-42.
Singer E., Markó L., Paragas N. et al. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications // Acta Physiol. 2013. (4). 63–72.
Smirnov A.V., Khasun M., Kayukov I.G. el al. Uromodulin and severity of tubulointerstital damage in patients with nephropathy // Nefrologiya = Nephrology. 2015. (2). 49-54. [In Russian].
Solini A., Santini E., Madec S. et al. Retinol-binding protein-4 in women with untreated essential hypertension // Am. J. Hypertens. 2009. (9). 1001-1006.
Suthanthiran M., Gerber L.M., Schwartz J.E. et al. Circulating transforming growth factor-β1 levels and the risk for kidney disease in African Americans // Kidney Int. 2009. 76. (1). 72–80.
Vel’kov V.V. NGAL — "renal troponin": an early marker of acute kidney injury. Pushchino, 2011. 55 p.
Véniant M., Menard J., Bruneval P. et al. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver// J. Clin Invest. 1996. 98. 1966-1970.
Waanders F., Vaidya V.S., van Goor H. et al. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic-proteinuric kidney disease: A post hoc analysis of a randomized controlled trial // Am. J. Kidney Dis. 2009. 53. (1). 16-25.
Yu L., Border W., Anderson I. et al. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect // Kidney Int. 2004. 66. 1774–1784.
Yu X.J., Li Y.J., Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits // Life Sci. 1994. 54. 753-758.
Zeisberg M., Sugimoto H. et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury // Nat. Med. 2003. 9. 964–968.